John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Metastatic pancreatic adenocarcinoma: Yesterday... Now... Tomorrow... Ever Volume 24, supplement 2, Juin 2017

Author
Centre Léon Bérard,
département de cancérologie médicale,
28 rue Laennec,
69373 Lyon cedex 08,
France

Metastatic pancreatic adenocarcinomas are often diagnosed with concomitant metastases. This stage is incurable with a survival of less than one year. Patient's management is based on chemotherapy and best supportive care. After years of negative phase III clinical trials, FOLFIRINOX and gemcitabine-nab-paclitaxel have demonstrated their superiority over gemcitabine alone. Recently, liposomal irinotecan in association with fluoro-uracile has also shown interesting results in the second-line setting. Other agents are currently investigated with potential new therapeutic regimens to define.